Moderna

[ASCO2024] Moderna's individualized neoantigen therapy shows broad efficacy in cancer treatment - koreabiomed.com

Moderna’s individualized neoantigen therapy demonstrated broad efficacy in cancer treatment at ASCO2024. As a leading platform player, Moderna’s positive data reinforces investor confidence in the scalability and clinical utility of mRNA-based personalized vaccines across diverse tumor types.